SCHEMBL429374

SCHEMBL429374

CC(OCCN1CCCCC1)(c1ccc(N)cc1)C(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HRH3 Q9Y5N1 9/20 0.48
CHRM2 P08172 1/20 0.48
HTR1A P08908 1/20 0.48
ADRA2A P08913 1/20 0.48
CHRM1 P11229 1/20 0.48
DRD1 P21728 1/20 0.48
TBXA2R P21731 1/20 0.48
ACHE P22303 1/20 0.48
SLC6A2 P23975 1/20 0.48
SLC6A4 P31645 1/20 0.48
ADRA1A P35348 1/20 0.48
OPRM1 P35372 1/20 0.48
DRD3 P35462 1/20 0.48
SLC6A3 Q01959 1/20 0.48
KCNH2 Q12809 1/20 0.48
PSMB1 P20618 2/20 0.48
PSMB5 P28074 2/20 0.48
PSMB2 P49721 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL426819 0.88 SMN1; SMN2 (0.53) ALDH1A1SMN1; SMN2HRH3CHRM2HTR1A
SCHEMBL447615 0.83 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2HRH3CHRM2HTR1A
SCHEMBL464533 0.72 SMN1; SMN2 (0.51) ALDH1A1SMN1; SMN2HRH3CHRM2HTR1A
SCHEMBL429377 0.71 RORC (0.36) ALDH1A1MAOB
SCHEMBL15315135 0.69 RORC (0.32) ALDH1A1SMN1; SMN2SLC6A2SLC6A4ADRA1A
SCHEMBL23724061 0.68 LTA4H (0.87) HRH3KCNH2PSMB1PSMB5PSMB2
SCHEMBL3937460 0.68 LTA4H (0.87) HRH3KCNH2PSMB1PSMB5PSMB2
SCHEMBL30617893 0.68 CHRM2 (0.84) ALDH1A1SMN1; SMN2HRH3CHRM2HTR1A
SCHEMBL6268349 0.68 LTA4H (0.44) ALDH1A1SMN1; SMN2HRH3CHRM2HTR1A
SCHEMBL444836 0.68 LTA4H (0.53) SMN1; SMN2HTR1ALTA4HKDM4EPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642624-B2 Substituted alkylamine derivatives and methods of use AMGEN INC. (US) 2014-02-04 US disclosed
US-20130273004-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2013-10-17 US disclosed
US-20120065185-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130273004-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE AADAC, NAT1, PIGO ALDH1A1 327/4885SMN1; SMN2 1829/4885HRH3 452/4885
US-20120065185-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE AADAC, NAT1, PIGO ALDH1A1 327/4885SMN1; SMN2 1829/4885HRH3 452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.